Expression of smad2/3 in experimental rat hepatocellular carcinoma

胡志英,胡锡琪,朱世能,顾映红
DOI: https://doi.org/10.3969/j.issn.1009-3079.2002.03.009
2002-01-01
World Chinese Journal of Digestology
Abstract:AIM: To observe the expression of smad2/3 in experimental rat hepatocellular carcinoma (HCC). METHODS: Expression of smad2/3 in liver tissues from 3'-Me-DAB treated rat liver cancer model was detected with immunohistochemical staining to investigate the significance of smad2/3 in carcinogenesis of HCC. RESULTS: During the pathogenesis of HCC, the expression of smad2 was obviously stronger than smad3 in proliferative and dysplastic bile duct cells, and hepatocytes. The positive rates of smad2 and smad3 were 100 % (19/19) and 15.8 % (3/19) (P < 0.01) respectively. Smad3 occurred predominantly in hepatic stellate cells (HSCs) and myofibroblasts. Smad2 was detected in 100 % (11/11) of HCC, while smad3 in only 9.1%(1/11) (P<0.01). CONCLUSION: TGF-β produced by proliferative and dysplastic bile duct cells, hepatic stellate cells and myofibroblasts may activate smad2/3, which are essential components of the signaling cascade of TGF-β famlily, resulted in proliferation, dysplasia and carcinogenesis.
What problem does this paper attempt to address?